Imelasomeran is a component of a bivalent COVID-19 mRNA vaccine encoding the viral spike protein of Omicron variant lineage BA.1. Imelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine.
- Mechanism
- Curator reviewed · 4 references
Moderna's COVID-19 mRNA vaccine is composed of synthetic nucleoside-modified messenger RNA (mRNA) encapsulated in lipid nanoparticle (LNP) which codes for the full-length, pre-fusion stabilized spike protein (S) of SARS-CoV-2. The S glycoprotein is a large transmembrane protein that plays a critical role in viral attachment, fusion, and entry into the host cell. Upon vaccination, human cells express the SARS-CoV-2 S antigen and immune response to the S antigen is elicited, leading to protection against SARS-CoV-2.
Imelasomeran is a component of one of Moderna's bivalent COVID-19 mRNA vaccines. It encodes the pre-fusion stabilized S glycoprotein of SARS-CoV-2 Omicron variant B.1.1.529 in order to elicit specific protection against this variant.
- Primary indication
- The Bivalent Moderna COVID-19 Vaccine (Original and Omicron BA.1) is a combination of imelasomeran and elasomeran (i.e. the monovalent [Moderna COVID-19 Vaccine]).Curator reviewed · 2 structured indications
- First approval
- Canada, 2023
Resolves to
What you can answer from here — as of July 26, 2025
Which other approved drugs treat the same conditions as Imelasomeran, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account